Blend of cellulose ester and enteric polymers for delayed and enteric coating of core tablets of hydrophilic and hydrophobic drugs
-
Add time:08/13/2019 Source:sciencedirect.com
The focus of this work was to explore feasibility of using blends of cellulose esters (CA 320S, CA 3980-10 or CAB 171-15) and enteric polymers (C-A-P, Eudragit® L100 or HPMCP HP-55) for delayed and enteric coating of tablets containing either diclofenac sodium (DFS, high dose) or prednisone (PDS, low dose) drug. The core tablets of DFS or PDS were coated with polymer blends to achieve approximate weight gain of 5% and 10%. The coated tablets were characterized for dissolution (0.1 N HCl and phosphate buffer pH 6.8) and surface morphology. The surface morphology of CA 398-10 or CAB 171-15 based polymer blends was rough and fibrous. Less than 0.5% drug was dissolved in 120 min from 5% w/w coated tablets in acid-phase dissolution testing. The dissolution in phosphate buffer pH 6.8 medium varied from 16.2 ± 0.2 to 98 ± 2.1%, and 30.1 ± 0.5% to 101.7 ± 3.4% in 120 min from DFS and PDS coated tablets, respectively. Dissolution was less in CA 320S based blends compared to CA 398-10 or CAB 171-15 blends in phosphate buffer medium. Furthermore, there were no significant differences observed in dissolution profiles of coated tablets of DFS or PDS. This can be explained by dose of the drugs. Additionally, dissolution was higher in tablets coated with enteric polymer alone compared with the blends. In conclusion, core tablets can be coated with cellulose ester and enteric polymers blend to impart both delayed and enteric release feature to the tablets containing hydrophilic or hydrophobic drug.
We also recommend Trading Suppliers and Manufacturers of Diclofenac Ethyl Ester (cas 15307-77-4). Pls Click Website Link as below: cas 15307-77-4 suppliers
Prev:Evaluation of developmental toxicity and teratogenicity of diclofenac using Xenopus embryos
Next:Formulation of diclofenac for dermal delivery) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Formulation of diclofenac for dermal delivery08/14/2019
- Evaluation of developmental toxicity and teratogenicity of diclofenac using Xenopus embryos08/12/2019
- A novel electrochemiluminescent immunoassay for diclofenac using conductive polymer functionalized graphene oxide as labels and gold nanorods as signal enhancers08/11/2019
- Bioconversion of non-steroidal anti-inflammatory drugs diclofenac and naproxen by chloroperoxidase08/10/2019
- The Hydrolysis of Diclofenac Esters: Synthetic Prodrug Building Blocks for Biodegradable Drug–Polymer Conjugates08/09/2019
- Long-Acting Diclofenac Ester Prodrugs for Joint Injection: Kinetics, Mechanism of Degradation, and In Vitro Release From Prodrug Suspension08/08/2019
- Plasmonic sensor for on-site detection of diclofenac molecules08/07/2019
- Delivery and Biodistribution of Traceable Polymeric Micellar Diclofenac in the Rat08/06/2019
-
Health and Chemical more >
-
Related Products
- Diclofenac Diethylamine
- Diclofenac epolamine
- Diclofenac Potassium
- Diclofenac sodium
- Ethyl (13-cis)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoate
- ethyl (1R,2R)-1-phenyl-2-(trideuteriomethylamino)cyclohex-3-ene-1-carboxylate,hydrochloride
- Ethyl (1S,2R)-2-(dimethylamino)-1-phenylcyclohex-3-ene-1-carboxylate hydrochloride
- Ethyl (2,4,6-trimethylbenzoyl) phenylphosphinate
- Ethyl (2-amino-4-hydroxy-6-methyl-5-pyrimidinyl)acetate
- Ethyl (2-bromopropionamido)acetate


